GSK’s $300M Acquisition of Chimagen’s CMG1A46: A Deep Dive into B Cell-Targeted Trispecific T Cell Engagers
November 4, 2024
On October 29, GSK made headlines with a $300 million upfront payment to acquire Chimagen Biosciences’ clinical-stage asset, CMG1A46, a dual-target CD19/CD20 trispecific T cell engager (TCE). This acquisition signals GSK’s commitment to advancing therapies for B-cell-driven autoimmune diseases, such as systemic lupus erythematosus and lupus nephritis, with possible applications in other autoimmune conditions. B […]
